CD159a (NKG2A) Antibody Kit, anti-human, PE, REAlease® from MILTENYI BIOTEC B.V. & Co. KG

Search, find, compare suppliers for CD159a (NKG2A) Antibody Kit, anti-human, PE, REAlease® products.

Edit 
Product NameCD159a (NKG2A) Antibody Kit, anti-human, PE, REAlease®
DescriptionCD159a (NKG2A) Antibody Kit, anti-human, PE, REAlease®. Clone REAL283 is an antibody fragment derived from the full CD159a (NKG2A) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL283 recognizes CD159a, an inhibitory natural killer (NK) cell receptor. CD159a forms heterodimer with CD94 and contains a C-type lectin ectodomain. Inhibitory signal is transmitted by the heterodimer via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and upon ligand engagement, ITIMs are phosphorylated and transmit signal through docking of various tyrosine phosphatases. CD159a/CD94 binds non-classical MHC class I protein, HLA-E. Expression of CD159a is found mainly on NK cells and on subsets of CD8+ cells. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
Size100 tests
Concentration1:50
ApplicationsFlow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence
Other NamesKLRC1, CD159a, NKG2, NKG2A
Gene, Accession, CAS #n/a
Catalog #130-122-642
Price$425
Order / More InfoCD159a (NKG2A) Antibody Kit, anti-human, PE, REAlease® from MILTENYI BIOTEC B.V. & Co. KG
Product Specific ReferencesBoyington, J. C. et al. (1999) Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity 10 (1): 75-82. | Sullivan, L. C. et al. (2007) The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 27 (6): 900-911. | Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10 (10): e0139603. | Veluchamy, J. P. et al. (2017) High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol. Immunother. 66: 51-61. | Jacomet, F. et al. (2017) The hypothesis of the human iNKT/innate CD8+ T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia. Front Immunol 7: 688.
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197

macs@miltenyibiotec.de

https://www.miltenyibiotec.com

Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Products

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.